All In Biotech

Drug Trial Radar · NCT03175367

Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia

A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Doses and Dose Regimens of Evinacumab in Patients With Persistent Hypercholesterolemia Despite Maximally Tolerated Lipid Modifying Therapy

Last checked: Nov 20, 2026Latest source record: Feb 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 272 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

272

Actual

Start

Nov 10, 2017

Primary completion

May 22, 2020

Study completion Dec 14, 2020

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Jun 5, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the reduction of LDL-C by evinacumab in comparison to placebo after 16 weeks in patients with primary hypercholesterolemia (HeFH, or non-HeFH with a history of clinical ASCVD) with persistent hypercholesterolemia despite receiving maximally-tolerated LMT. Persistent hypercholesterolemia is defined as LDL-C ≥70 mg/dL (1.81 mmol/L) for those patients with clinical ASCVD and LDL-C ≥100 mg/dL (2.59 mmol/L) for those patients without clinical ASCVD.

Conditions

  • Hypercholesterolemia

Interventions

  • EvinacumabDrug

    SC or IV administration

  • Matching placeboDrug

    SC or IV administration

  • Background Lipid Modifying Therapy (LMT)Other

    All participants should be on a stable, maximally tolerated statin throughout the duration of the study. The dose of statin and of PCSK9 inhibitor, such as alirocumab or evolocumab, as well as other LMT (if applicable), should remain stable throughout the study duration, from screening through the end of study (EOS) visit.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 16 (Intent-to-Treat [ITT] Estimand)Time frame: Baseline and Week 16

Locations

95 sites in 20 countries. Site status is shown where the registry gives one.

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Office of Dr. John D Homan MD

    Newport Beach, California

  • Preventive Cardiology Inc

    Boca Raton, Florida

  • Care Research Center Inc

    Doral, Florida

  • Florida Lipid Institute

    Winter Park, Florida

  • St. Vincent Medical Group, Inc

    Indianapolis, Indiana

  • University of Kansas Medical Center

    Kansas City, Kansas

  • EMMC Northeast Cardiology Assocites

    Bangor, Maine

  • University of Maryland School of Medicine

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Heart Health Cardiology

    Grand Rapids, Michigan

  • Minneapolis Heart Institute Foundation

    Minneapolis, Minnesota

  • University of Minnesota

    Minneapolis, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Mt Sinai Ichan Medical Institute

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Rowan Diagnostic Clinic

    Salisbury, North Carolina

  • Capital Area Research, LLC

    Camp Hill, Pennsylvania

  • The University Of Texas Health Science Center Houston

    Houston, Texas

  • San Antonio Premiere Internal Medicine

    San Antonio, Texas

  • Clear Clinical Research, LLC

    Schertz, Texas

  • PharmaTex Research

    Tyler, Texas

  • Wasatch Clinical Research

    Salt Lake City, Utah

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia

  • Redcliffe Hospital

    Redcliffe, Queensland, Australia

  • Medizinische Universitaetsklinik Graz

    Graz, Austria

  • University Hospital Innsbruck - Tyrolean Hospital

    Innsbruck, Tyrol, Austria

  • Robarts Research Institute

    London, Ontario, Canada

  • SKDS Research Inc.

    Newmarket, Ontario, Canada

  • Centre Etudes Cliniques Econogene-21

    Chicoutimi, Quebec, Canada

  • Clinique des maladies lipidiques de Quebec

    Québec, Quebec, Canada

  • University Hospital, Charles University

    Hradec Králové, Czechia

  • Ikem Institut Klinicke A Experimentalni Mediciny

    Prague, Czechia

  • CCR Prague, S.R.O

    Prague, Prague 3, Czechia

  • Univerzita Karlova v Praze 1 Lekarska Fakulta

    Karlov, Praha 2, Czechia

  • Sydvestjysk Sygehus

    Esbjerg, Denmark

  • Regionshospitalet Herning

    Herning, Denmark

  • Houpital Du Bocage

    Dijon, France

  • Hopital G Et R Laennec

    Nantes, Cedex, France

  • Edith Wolfson Medical Center

    Holon, Israel

Showing 40 of 95 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.